These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 21745011

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The search for optimal response prediction in cancer leads to a personalized approach.
    Van Cutsem E, Ciardiello F.
    Target Oncol; 2010 Mar; 5(1):3-4. PubMed ID: 20349283
    [No Abstract] [Full Text] [Related]

  • 4. Impact of genomics on personalized cancer medicine.
    Arteaga CL, Baselga J.
    Clin Cancer Res; 2012 Feb 01; 18(3):612-8. PubMed ID: 22298893
    [Abstract] [Full Text] [Related]

  • 5. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
    Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ.
    Crit Rev Oncol Hematol; 2012 Feb 01; 81(2):103-22. PubMed ID: 21546262
    [Abstract] [Full Text] [Related]

  • 6. Predicting drug response based on gene expression.
    Robert J, Vekris A, Pourquier P, Bonnet J.
    Crit Rev Oncol Hematol; 2004 Sep 01; 51(3):205-27. PubMed ID: 15331079
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Predicting cancer drug response by proteomic profiling.
    Ma Y, Ding Z, Qian Y, Shi X, Castranova V, Harner EJ, Guo L.
    Clin Cancer Res; 2006 Aug 01; 12(15):4583-9. PubMed ID: 16899605
    [Abstract] [Full Text] [Related]

  • 9. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
    Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M.
    Pharmacol Rev; 2003 Mar 01; 55(1):57-103. PubMed ID: 12615954
    [Abstract] [Full Text] [Related]

  • 10. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE, Katsios CS, Tzaphlidou M, Roukos DH.
    Expert Rev Anticancer Ther; 2012 Jul 01; 12(7):861-4. PubMed ID: 22845399
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A, Livney YD, Broxterman HJ, Assaraf YG.
    Drug Resist Updat; 2011 Jun 01; 14(3):150-63. PubMed ID: 21330184
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
    Efferth T, Konkimalla VB, Wang YF, Sauerbrey A, Meinhardt S, Zintl F, Mattern J, Volm M.
    Clin Cancer Res; 2008 Apr 15; 14(8):2405-12. PubMed ID: 18413831
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Refocusing the war on cancer: the critical role of personalized treatment.
    Potti A, Schilsky RL, Nevins JR.
    Sci Transl Med; 2010 Apr 21; 2(28):28cm13. PubMed ID: 20410527
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.